Related Experiment Video
Updated: May 3, 2026
08:46
Implementation of In Vitro Drug Resistance Assays: Maximizing the Potential for Uncovering Clinically Relevant Resistance Mechanisms
Published on: December 9, 2015
12.8K
Overcoming Drug Resistance by Targeting Cancer Bioenergetics with an Activatable Prodrug.
Amit Sharma1,2, Min-Goo Lee3,2, Hu Shi4,5,2
1Department of Chemistry, Korea University, Seoul 02841 Korea.
Chem
|January 20, 2025
Summary
This study introduces Conjugate C1, a novel approach to overcome chemotherapy resistance in cancer. By reprogramming cancer cell metabolism and targeting drug delivery, it enhances apoptosis and inhibits tumor regrowth with minimal toxicity.
Area of Science:
- Oncology
- Cancer Metabolism
- Drug Resistance
Background:
- Chemotherapeutic resistance is a significant challenge in cancer treatment, leading to poor patient outcomes.
- Understanding the mechanisms of resistance, such as altered mitochondrial metabolism and drug efflux pumps, is crucial for developing effective therapies.
Purpose of the Study:
- To develop a novel therapeutic strategy to overcome chemoresistance by targeting mitochondrial metabolism and drug efflux.
- To evaluate the efficacy and toxicity of a new conjugate, C1, in preclinical cancer models.
Main Methods:
- Reprogramming oncogene-directed alterations in mitochondrial metabolism.
- Developing a conjugate (C1) to circumvent drug efflux pumps.
- Assessing C1 efficacy in human cancer cells and Dox-resistant xenograft tumor models.
Main Results:
- Conjugate C1 demonstrated increased cancer cell apoptosis and inhibited the regrowth of drug-resistant tumors.
- The compound exhibited minimal whole-animal toxicity.
- C1 effectively targeted the mitochondrion and then the nucleus with the active drug.
Conclusions:
- Conjugate C1 represents a promising approach to evade chemoresistance by restoring normal mitochondrial oxidative phosphorylation.
- This strategy offers a potential new avenue for treating drug-resistant cancers with improved safety profiles.
More Related Videos
Related Concept Videos
02:53Adaptive Mechanisms in Cancer Cells
5.7K
Cancer cells accumulate genetic changes at an abnormally rapid rate due to the defects in the DNA repair mechanisms. From an evolutionary perspective, such genetic instability is advantageous for cancer development. Mutant cell lines accumulate a series of beneficial mutations that contribute to their progression into cancer.
Some of the advantages that cancer cells have on normal cells include - enhanced ability to divide without terminally differentiating, induce new blood vessel formation,...
Some of the advantages that cancer cells have on normal cells include - enhanced ability to divide without terminally differentiating, induce new blood vessel formation,...
5.7K
02:57Targeted Cancer Therapies
7.4K
The targeted cancer therapies, also known as “molecular targeted therapies,” take advantage of the molecular and genetic differences between the cancer cells and the normal cells. It needs a thorough understanding of the cancer cells to develop drugs that can target specific molecular aspects that drive the growth, progression, and spread of cancer cells without affecting the growth and survival of other normal cells in the body.
There are several types of targeted therapies against...
There are several types of targeted therapies against...
7.4K
02:56Treatment Resistant Cancers
3.2K
Cancer is the second leading cause of death in the United States. A cancer cell is genetically unstable and hence can mutate faster. They can also modify their microenvironment and escape immune surveillance. The difficulties in treating cancer are further compounded by the emergence of rapid resistance to anticancer drugs. The most common ways to attain resistance in cancer cells include alteration in drug transport and metabolism, modification of drug target, elevated DNA damage response, or...
3.2K
02:50Combination Therapies and Personalized Medicine
4.8K
Combining two or more treatment methods increases the life span of cancer patients while reducing damage to vital organs or tissue from the overuse of a single treatment. Combination therapy also targets different cancer-inducing pathways, thus reducing the chances of developing resistance to treatment.
The combination of the drug acetazolamide and sulforaphane is a good example of combination therapy to treat cancer. The cells in the interior of a large tumor often die due to the hypoxic and...
The combination of the drug acetazolamide and sulforaphane is a good example of combination therapy to treat cancer. The cells in the interior of a large tumor often die due to the hypoxic and...
4.8K
01:26Targets for Drug Action: Overview
6.0K
Drugs target macromolecules to modify ongoing cellular processes. Primary drug targets include receptors, ion channels, transporters, and enzymes.
Receptors are either membrane-spanning or intracellular proteins, which upon binding a ligand, get activated and transmit the signal downstream to elicit a response. Drugs bind receptors, either mimicking the action of endogenous ligands or blocking the receptor activity to bring about a modified response. Nearly 35% of approved drugs target the G...
Receptors are either membrane-spanning or intracellular proteins, which upon binding a ligand, get activated and transmit the signal downstream to elicit a response. Drugs bind receptors, either mimicking the action of endogenous ligands or blocking the receptor activity to bring about a modified response. Nearly 35% of approved drugs target the G...
6.0K
01:30Prodrugs
2.4K
Prodrugs are a class of pharmaceutical compounds that undergo a biotransformation process within the body to be converted into a pharmacologically active drug. Prodrugs are designed to improve the therapeutic properties of the parent drug, such as enhancing bioavailability, increasing stability, or reducing toxicity. The concept of prodrugs revolves around modifying the chemical structure of the original drug to make it more effective or convenient for administration.
Prodrugs help overcome...
Prodrugs help overcome...
2.4K